Baseline Predictors for Five-Year Visual Acuity Outcomes in the Comparison of AMD Treatment Trials.

ABSTRACT:

Purpose

To determine baseline predictors of visual acuity (VA) outcomes at 5 years after initiating treatment with ranibizumab or bevacizumab for neovascular age-related macular degeneration (AMD).

Design

Secondary analysis of data from a cohort study.

Participants

Patients enrolled in the Comparison of AMD Treatments Trials (CATT) who completed a 5-year follow-up visit.

Methods

Participants were randomly assigned to ranibizumab or bevacizumab and to 1 of 3 dosing regimens. After two years, patients were released from the clinical trial protocol, and were recalled for examination at 5 years. Trained readers evaluated baseline lesion features, fluid and thickness. Baseline predictors were determined using univariate and multivariate regression analysis.

Main

SUBMITTER: Ying GS 

PROVIDER: S-EPMC6009839 | biostudies-literature | 2018 Jun

REPOSITORIES: biostudies-literature